Look Beyond
Look Beyond
the Limits
in Ophthalmology
Join us as we enter the new era of vision.
The Genentech
Commitment
Commitment
Considered the founder of the industry, Genentech has been delivering on the promise of biotechnology for more than 40 years
Realities of
Retinal Disease
Retinal Disease
Focused on tackling the leading causes of vision loss to better meet patient needs
Genentech
Products
Products
Leading the industry with one of the strongest research and development pipeline
DME=diabetic macular edema; nAMD=neovascular age-related macular degeneration.
Here at Genentech, we are transforming ophthalmology
… and opening up The Window to Change.
Our Commitment to Ophthalmology
Vision loss affects more than 250 million people worldwide, making it one of the leading public health issues in the world. Currently, visual impairment is expected to reach 43 million patients with DME and 29 million patients with nAMD by 2040. At Genentech, we are focused on tackling these problems from a new perspective. With the global retina community, we are changing how we approach medical innovation by exploring cutting-edge technology and pioneering new therapies. We are changing how patients experience their care, for the better, by looking beyond the therapy, developing integrated digital solutions that support patients and physicians every step of the way. Join us as we lead and help shape the future of ophthalmology, together.